BioSpace News Archive

Company appoints healthcare data & analytics innovator Brigham Hyde, Ph.D. to lead platform launch

Dr. Michael Anger Will Lead Medical Department for Leading Provider of Kidney Care Products

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its lead product Berubicin.

Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced the appointment of David Michelson, M.D., as Chief Medical Officer.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2020 on Wednesday, May 6, 2020, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2020 results as well as expectations for the future via conference call on Wednesday, May

Highlights: Statistically significant reduction in MRSA superbug bacterial load and higher percentage of wound contraction with RECCE ® 327 as compared to Soframycin in rat model for topical burns Study reinforces the potential of RECCE ® 327 against drug-resistant superbugs

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that two e-posters highlighting efficacy and safety results from its Phase 3 program are available for online viewing from the cancelled Annual Regional Anesthesiology and Acute Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine (“ASRA”). The meeting w

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.Q TM platform. The goal of the test is to provide early insight

In response to the need for critical care during the COVID-19 crisis, Carestream Health has increased production of its portable diagnostic imaging systems.

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure